Trials / Unknown
UnknownNCT02960607
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
A Phase II Study of High-dose Icotinib in Previously Treated Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate whether high-dose icotinib treatment beyond disease progression is beneficial for NSCLC patients who have EGFR mutation and who have responded to EGFR TKI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icotinib | Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred. |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2018-01-01
- First posted
- 2016-11-09
- Last updated
- 2016-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02960607. Inclusion in this directory is not an endorsement.